Bio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018.

Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law.

He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy.

He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm.

Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness.